Resultados de procura - Charles D. Blanke

Limitar resultados
  1. 1
    Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation [letter]

    Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation [letter] por Robert Hromas, Kenneth Cornetta, Edward F. Srour, Charles D. Blanke, ER Broun

    Publicado 1994
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Oxaliplatin: Hohe Aktivität in allen Stadien des Kolonkarzinoms

    Oxaliplatin: Hohe Aktivität in allen Stadien des Kolonkarzinoms por Paulo M. Hoff, Leonard B. Saltz, Charles D. Blanke, Eric van Custem

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials

    Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials por Joseph M. Unger, Charles D. Blanke, Michael LeBlanc, Dawn L. Hershman

    Publicado 2020
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic

    Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic por Joseph M. Unger, Hong Xiao, Michael LeBlanc, Dawn L. Hershman, Charles D. Blanke

    Publicado 2021
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Characterizing 18 Years of the Death With Dignity Act in Oregon

    Characterizing 18 Years of the Death With Dignity Act in Oregon por Charles D. Blanke, Michael LeBlanc, Dawn L. Hershman, Lee M. Ellis, Frank L. Meyskens

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)

    Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415) por Philip J. Gold, Bryan Goldman, Syma Iqbal, Lawrence P. Leichman, Wu Zhang, Heinz‐Josef Lenz, Charles D. Blanke

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

    Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors por George D. Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova, Charles D. Blanke, Heikki Joensuu, Margaret von Mehren

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies

    A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies por Patricia A. Deverka, Rick Bangs, Karma L. Kreizenbeck, Deborah M Delaney, Dawn L. Hershman, Charles D. Blanke, Scott D. Ramsey

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  9. 9
    Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

    Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer por Syma Iqbal, Bryan Goldman, Cecilia M. Fenoglio‐Preiser, Heinz‐Josef Lenz, W. Zhang, K. D. Danenberg, Stephen Shibata, Charles D. Blanke

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Let’s Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine

    Let’s Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine por Laura Tenner, Fay J. Hlubocky, Charles D. Blanke, Thomas W. LeBlanc, Jonathan M. Marron, Molly McGinnis, Rebecca Spence, Lynne P. Taylor

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Trends in Medical Aid in Dying in Oregon and Washington

    Trends in Medical Aid in Dying in Oregon and Washington por Luai Al Rabadi, Michael LeBlanc, Taylor Bucy, Lee M. Ellis, Dawn L. Hershman, Frank L. Meyskens, Lynne P. Taylor, Charles D. Blanke

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)

    Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414) por Michael Tomblyn, Bryan Goldman, Charles R. Thomas, Jacqueline Benedetti, Heinz‐Josef Lenz, Vivek Mehta, Thaddeus Beeker, Philip J. Gold, James L. Abbruzzese, Charles D. Blanke

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

    S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma por Anthony B. El-Khoueiry, Cathryn Rankin, A.B. Siegel, Syma Iqbal, I-Y Gong, Kenneth C. Micetich, Omar Kayaleh, H-J Lenz, Charles D. Blanke

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

    SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma por Anthony B. El-Khoueiry, Cathryn Rankin, Edgar Ben‐Josef, Heinz‐Josef Lenz, Philip J. Gold, Robert D. Hamilton, Rangaswamy Govindarajan, Cathy Eng, Charles D. Blanke

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

    Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer por Kathy D. Miller, Joel Picus, Charles D. Blanke, William J. John, Jeffrey W. Clark, Lawrence N. Shulman, D. Thornton, Eric K. Rowinsky, Patrick J. Loehrer

    Publicado 2000
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials

    Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials por Charles D. Blanke, Brian M. Bot, David M. Thomas, Archie Bleyer, Claus-Henning Köhne, Michel Seymour, Aimery de Gramont, Richard M. Goldberg, Daniel J. Sargent

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

    Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) por Robert P. Whitehead, Cathryn Rankin, Paulo M. Hoff, Philip J. Gold, Kevin G. Billingsley, Robert Chapman, Lucas Wong, John H. Ward, James L. Abbruzzese, Charles D. Blanke

    Publicado 2008
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal

    End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal por Carmen J. Allegra, Charles D. Blanke, Marc Buyse, Richard M. Goldberg, Axel Grothey, Neal J. Meropol, Leonard B. Saltz, Alan P. Venook, Greg Yothers, Daniel J. Sargent

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  19. 19
    Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

    Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gem... por Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan, Heinz‐Josef Lenz, Andrew M. Lowy, Robert P. Whitehead, Takeru Wakatsuki, Syma Iqbal, Rakesh Gaur, Jacqueline Benedetti, Charles D. Blanke

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Phase 2 study of <scp>MK</scp>‐2206, an allosteric inhibitor of <scp>AKT</scp>, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (<scp>S</scp>1005)

    Phase 2 study of <scp>MK</scp>‐2206, an allosteric inhibitor of <scp>AKT</scp>, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative... por Ramesh K. Ramanathan, Shannon McDonough, Hagen F. Kennecke, Syma Iqbal, Joaquina Baranda, Tara Elisabeth Seery, Howard J. Lim, Aram F. Hezel, Gina M. Vaccaro, Charles D. Blanke

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: